Icatibant Cipla (Icatibant)

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. Dosing regimens are individualized, and patients should follow the prescriber’s instructions without deviation.

Safety of icatibant in pregnancy and while breastfeeding has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Icatibant Cipla, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain where required) and import documentation.

The primary alternative for HAE attacks is a C1‑esterase inhibitor (e.g., Berinert). Icatibant directly blocks the bradykinin B2 receptor, offering a rapid subcutaneous option, whereas C1‑esterase inhibitors replace deficient protein and are administered intravenously. Choice depends on clinical response, administration preferences and patient-specific factors.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, consult the product’s stability guidelines before use.

Icatibant is administered as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver. The site should be rotated for repeated doses to minimize local reactions.

The most serious risks associated with icatibant include anaphylaxis, severe angioedema affecting the airway, and significant hypotension. Patients should be observed after injection for any signs of allergic reaction or worsening swelling and receive immediate medical attention if these occur.

Icatibant should not be used in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with a history of severe angioedema unrelated to hereditary angioedema, as well as those taking ACE inhibitors or ARBs without proper medical supervision.